Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Fig. 2

DAS28-CRP. a DAS28-CRP adjusted mean change from baseline and unadjusted box and whisker plot of unadjusted change from baseline by treatment over time (combined b.i.d. and t.i.d. dosing). b DAS28-CRP adjusted mean change from baseline by dosing regimen. b.i.d., twice daily; CRP, C-reactive protein; DAS28-CRP, disease activity score for 28 joints using CRP value; t.i.d., three times daily

Back to article page